Trial Profile
Prospective multicenter trial on the identification of novel biomarkers for Sunitinib therapy in the treatment of Japanese patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2017
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Sponsors Pfizer
- 21 Jan 2013 New trial record